ExpreS2ion Biotech Holding AB Working Capital to Net Assets Ratio
ExpreS2ion Biotech Holding AB working capital to net assets ratio. ExpreS2ion Biotech Holding AB (EXPRS2) has a Working Capital to Net Assets ratio of 75.9% as of March 2026. Working capital of Skr20.05 Million (current assets of Skr43.02 Million minus current liabilities of Skr22.96 Million) is measured against net assets of Skr26.42 Million. A higher ratio indicates strong short-term liquidity financed by the equity base. Check EXPRS2 tangible net worth ratio to evaluate the tangible quality of the company's equity base.
WC/NA Ratio
Working Capital
Current Assets
Current Liabilities
Working Capital to Net Assets Ratio of ExpreS2ion Biotech Holding AB (2013–2025)
Working capital to net assets ratio of ExpreS2ion Biotech Holding AB from 2013 to 2025. This chart shows how ExpreS2ion Biotech Holding AB's Working Capital to Net Assets ratio has evolved across 13 annual periods from 2013 to 2025. As of March 2026, the ratio stands at 75.9%, reflecting working capital of Skr20.05 Million against net assets of Skr26.42 Million SEK. See ExpreS2ion Biotech Holding AB liquidity coverage in days to measure how many days the company can operate on defensive assets alone.
ExpreS2ion Biotech Holding AB Working Capital to Net Assets Ratio by Year (2013–2025)
ExpreS2ion Biotech Holding AB working capital to net assets ratio by year from 2013 to 2025. The table below presents the year-by-year Working Capital to Net Assets ratio for ExpreS2ion Biotech Holding AB from 2013 to 2025, covering 13 annual filings. Each row shows current assets, current liabilities, working capital, net assets, the ratio, and the change in percentage points compared to the prior year. For the complete balance sheet picture, see ExpreS2ion Biotech Holding AB asset portfolio.
| Year | WC/NA Ratio | Working Capital (SEK) | Net Assets | Current Assets | Current Liabilities | Change (pp) |
|---|---|---|---|---|---|---|
| 2025 | 82.0% | Skr29.27 Million | Skr35.69 Million | Skr57.53 Million | Skr28.26 Million | ▼ -6.0 pp |
| 2024 | 88.1% | Skr56.73 Million | Skr64.42 Million | Skr94.98 Million | Skr38.25 Million | ▲ +0.4 pp |
| 2023 | 87.6% | Skr57.28 Million | Skr65.36 Million | Skr68.67 Million | Skr11.38 Million | ▼ -9.6 pp |
| 2022 | 97.3% | Skr100.52 Million | Skr103.33 Million | Skr131.94 Million | Skr31.43 Million | ▼ -1.8 pp |
| 2021 | 99.0% | Skr139.00 Million | Skr140.35 Million | Skr146.46 Million | Skr7.46 Million | ▼ -0.6 pp |
| 2020 | 99.7% | Skr94.25 Million | Skr94.55 Million | Skr112.46 Million | Skr18.21 Million | ▼ -92.9 pp |
| 2019 | 192.6% | Skr-2.08 Million | Skr-1.08 Million | Skr10.14 Million | Skr12.21 Million | ▲ +122.9 pp |
| 2018 | 69.7% | Skr5.79 Million | Skr8.30 Million | Skr10.83 Million | Skr5.04 Million | ▲ +14.9 pp |
| 2017 | 54.8% | Skr3.69 Million | Skr6.74 Million | Skr6.05 Million | Skr2.36 Million | ▼ -8.9 pp |
| 2016 | 63.7% | Skr8.21 Million | Skr12.88 Million | Skr11.79 Million | Skr3.58 Million | ▼ -43.7 pp |
| 2015 | 107.4% | Skr-6.46 Million | Skr-6.01 Million | Skr3.64 Million | Skr10.10 Million | ▲ +43.5 pp |
| 2014 | 63.9% | Skr1.50 Million | Skr2.35 Million | Skr4.63 Million | Skr3.13 Million | ▲ +19.0 pp |
| 2013 | 45.0% | Skr868.07K | Skr1.93 Million | Skr3.04 Million | Skr2.18 Million | — |